Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Blood|December 8, 2009
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropeniaRekha Pal, Sara A Monaghan, Andrea Cortese Hassett, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 7, 2020
Defining Acute Myeloid Leukemia Ontogeny in Older PatientsMegan Melody, Andrew Kuykendall, David Sallman, et al.
Haematologica|October 7, 2017
Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromesThomas Cluzeau, Kathy L McGraw, Brittany Irvine, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 19, 2014
Pretransplantation 5-azacitidine in high-risk myelodysplastic syndromeTaiga Nishihori, Janelle Perkins, Asmita Mishra, et al.
European Journal of Haematology|April 17, 2010
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*Valeria Santini, Pierre Fenaux, Ghulam J Mufti, et al.
Cancer|July 12, 2008
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemHagop Kantarjian, Susan O'Brien, Farhad Ravandi, et al.
Leukemia Research|December 24, 2013
Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study modelPierre Fenaux, John F Seymour, Valeria Santini, et al.
Cancer Medicine|December 22, 2020
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research ConsortiumRami S Komrokji, Najla H Al Ali, David Sallman, et al.
Leukemia Research|November 8, 2017
Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidineMarie Sébert, Rami S Komrokji, Mikkael A Sekeres, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 28, 2009
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomideSheng Wei, Xianghong Chen, Kathy Rocha, et al.
Pageof 7